Cannara Biotech Announces Notice Of Annual General Meeting Of Shareholders To Be Held Virtually On January 25th, 2024
- None.
- None.
Shareholders are encouraged to vote on the matters before the meeting by proxy and to join the meeting by webcast. Those who attend the meeting by teleconference are requested to read the notes to form of proxy and then to, complete, sign and mail the enclosed form of proxy in accordance with the instructions set out in the proxy and in the information circular.
Holders of record of ordinary shares of the Company at the close of business on December 5, 2023 will be asked by the Company for disinterested shareholder approval for the extension of the expiry date of 3,723,800 options which are currently issued and outstanding to employees of the Company by two years, including 3,503,500 options which are currently issued to Company insiders. These options are set to expire five years from grant date, and the Company is seeking approval to amend the expiration to seven years from initial grant date. Shareholders will also be asked to approve the Company's rolling employee stock option plan and restricted share unit plan, as is required on an annual basis.
Shareholders will be able to join the annual general meeting by clicking on the link below:
To join the meeting via teleconference, please dial 1-650-479-3208 and use meeting code 2634 285 6848 and passcode LOVE2024.
*Note re Teleconference: Shareholders accessing the Meeting via Teleconference will not be able to vote or speak at the Meeting. To vote or speak at the Meeting, Shareholders will need to join the webcast and utilize the chat function during the Meeting. A moderator will be present to allow Shareholders to vote or speak at the Meeting at the appropriate time.
Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB) is a vertically integrated producer of affordable premium-grade cannabis and cannabis-derivative products for the Canadian markets. Cannara owns two mega facilities based in
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cannara-biotech-announces-notice-of-annual-general-meeting-of-shareholders-to-be-held-virtually-on-january-25th-2024-302014255.html
SOURCE Cannara Biotech Inc.
FAQ
When is Cannara Biotech Inc.'s annual general meeting of shareholders?
What is the purpose of the annual general meeting?
How can shareholders join the annual general meeting?
What is the link to join the annual general meeting via webcast?
How can shareholders vote or speak at the meeting if joining via teleconference?
What is the purpose of extending the expiry date of options?
What will shareholders be asked to approve at the meeting?
When is the deadline for shareholders to vote on the matters before the meeting?